Intravenous Immunoglobulin Market Report 2026

Intravenous Immunoglobulin Market Overview

• Intravenous Immunoglobulin market size has reached to $15.57 billion in 2025 • Expected to grow to $23.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Geriatric Population Fuels Growth In The Intravenous Immunoglobulin Market • Market Trend: A Breakthrough in Plasma-Derived Immunoglobulin Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Intravenous Immunoglobulin Market?

Intravenous immunoglobulin refers to a therapy used for the treatment of immunodeficient people. It is administered in the form of intravenous infusion. Infusion liquid is made from immunoglobulins collected from healthy individuals and purified to eliminate any blood-borne infection or impurity. The main types of intravenous immunoglobulin are Immunoglobulin G (IgE), Immunoglobulin M (IgM), Immunoglobulin A (IgA), (Immunoglobulin E (IgE), Immunoglobulin D (IgD). Immunoglobulin G refers to the most common immunoglobulin found in blood and other body fluids and defends the body against bacterial and viral infection. IgG is used to boost the body’s natural defense system. These are distributed through hospital pharmacy, retail pharmacy, and others, used in applications such as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, and others. The various end-users include hospitals, clinics, and home care.

What Is The Intravenous Immunoglobulin Market Growth Forecast?

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $23.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for home-based ivig therapy, development of biosimilar ivig products, integration of automated infusion technologies, expanding applications in neurological disorders, growth in emerging markets for immunoglobulin therapies. Major trends in the forecast period include personalized immunoglobulin therapy, home-based ivig administration, biosimilar development and adoption, enhanced purification and safety protocols, automated infusion systems.

Global Intravenous Immunoglobulin Market Segmentation

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D) 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels 3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications 4) By End-User: Hospitals, Clinics, Home Care

What Is The Driver Of The Intravenous Immunoglobulin Market?

The increasing geriatric population is expected to drive the intravenous immunoglobulin market forward. The geriatric population refers to the population above 65 years of age. As people grow old, their immunity does not work properly and there is a lack of antibodies. Therefore, they need immunoglobulins to provide them with antibodies. This increases demand for intravenous immunoglobulins and drives the intravenous immunoglobulin market forward. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based Nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. As a result, the increasing geriatric population will drive the growth of the intravenous immunoglobulin industry forward.

Key Players In The Global Intravenous Immunoglobulin Market

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Global Intravenous Immunoglobulin Market Trends and Insights

Major companies operating in the intravenous immunoglobin market are focused on introducing innovative products, such as plasma-derived medicines, and getting them approved by federal agencies, including the US FDA, to gain a competitive edge in the market. The introduction of an FDA-approved innovative IVIG solution signifies the approval of a novel intravenous immunoglobulin (IVIG) therapy by the U.S. Food and Drug Administration for the treatment of specific medical conditions. For instance, in June 2024, Biotest AG, a Germany-based supplier of plasma proteins and products company announced its first U.S. Food and Drug Administration (FDA) approval Yimmugo for the treatment of primary immunodeficiencies. As an intravenous immunoglobulin, Yimmugo contains pooled human plasma-derived immunoglobulin G (IgG), which plays a crucial role in immune support for patients with PIDs. The approval comes amid increasing demand for plasma-derived therapies, highlighting the need for effective treatments for patients with compromised immune systems. Yimmugo adds to Grifols' existing range of intravenous and subcutaneous immunoglobulins, providing more options for patients reliant on these essential medicines.

What Are Latest Mergers And Acquisitions In The Intravenous Immunoglobulin Market?

In February 2024, Ridgemont Equity Partners, a US-based equity investor company acquired American Outcomes Management for an undisclosed amount. This acquisition aligns with Ridgemont's strategic focus on the growing specialty infusion market, which is driven by an aging population with chronic conditions and a rising demand for at-home treatment options. American Outcomes Management is a US-based provider of intravenous immunoglobulin (IVIG) infusion therapy.

Regional Insights

North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Intravenous Immunoglobulin Market?

The intravenous immunoglobulin market consists of sales of intravenous immunoglobulin used for treating people with antibody deficiencies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intravenous Immunoglobulin Market Report 2026?

The intravenous immunoglobulin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous immunoglobulin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.